Why Product Information Controls Matter in Medicines Wholesale
The MHRA recently issued a Class 4 Medicines Defect Notification for Doncaster Pharma Limited’s parallel imported Hiprex 1g tablets.
The issue related to Braille embossing on the outer packaging of certain batches. The printed text on the outer packaging, immediate packaging and Patient Information Leaflet correctly stated the medicine strength as 1g, but the Braille on the outer packaging incorrectly stated 1mg.
The MHRA said the products remained within specification, there was no issue with product quality, and the affected batches were not being recalled. Healthcare professionals were advised to explain the Braille error to patients who rely solely on Braille when reading medicine cartons, if requested.
For medicines wholesale businesses, this is a useful reminder:
Product information controls matter.
What Happened and Why It Matters
This MHRA notification was not about a product quality failure.
It was about information on the packaging.
That may sound like a small detail, but in medicines supply, information is part of control.
The printed carton, the immediate packaging, the leaflet, the batch details, the Braille, supplier notices and customer communication all help the supply chain understand what the product is and how information should be passed on.
If one part of that information is wrong, the business needs a controlled way to respond.
That means knowing:
- Which batches are affected?
- Who needs to know?
- Does the Responsible Person need visibility?
- Do customers need communication?
- Are stock teams aware?
- What should be recorded?
- Is any follow-up action needed?
In regulated medicines wholesale, clear information is not optional. It supports safe, controlled and traceable supply.
What This Means for Medicines Wholesale Businesses
Medicines wholesale is often discussed in terms of licensing, storage, transport and inspection readiness.
Those areas are important.
But GDP quality systems also need to support product information control.
The MHRA explains that GDP requires medicines to be obtained from the licensed supply chain and consistently stored, transported and handled under suitable conditions. It also explains that MHRA inspections may review documents, stock management, storage areas, purchasing and sales functions, transportation arrangements and relevant personnel.
That means a wholesaler’s systems should be able to manage information issues as well as physical product issues.
A business may receive:
- Defect notifications
- Supplier notices
- Updated packaging information
- Patient Information Leaflet updates
- Recall communications
- Customer queries
- Accessibility-related packaging information
- Batch-specific notices
If there is no clear process, these updates can be missed, handled informally or recorded poorly.
That creates risk.
Why Accessibility Information Matters
Braille on medicine packaging is there to help people who rely on it identify products more safely and independently.
If Braille information is wrong, even where printed text is correct and product quality is not affected, the issue still needs attention.
For wholesalers and distribution businesses, the practical question is not only whether the product is defective.
The question is whether the business can manage the communication properly.
- Can affected batches be identified?
- Can customers be informed where needed?
- Can the supplier notice be stored?
- Can staff answer customer questions correctly?
- Can the Responsible Person see what happened?
- Can records show how the issue was handled?
These are the kinds of details that show whether a quality system is actually working.
Why Responsible Person Visibility Matters
The Responsible Person should have visibility over GDP quality risks that may affect product information, supplier communication, customer communication, defect notifications or documentation control.
That does not mean the Responsible Person personally handles every packaging notice.
But it does mean the business should have a clear route for important information to reach the right people.
A good process should answer:
- Who receives MHRA alerts and supplier notices?
- Who checks whether stock is affected?
- Who informs the Responsible Person?
- Who communicates with customers where needed?
- Who records the review?
- Who checks whether the issue is closed?
If those answers are unclear, the system may need strengthening.
What Businesses Should Check Now
If your business is involved in medicines wholesale, WDA(H) readiness, specialist distribution or ongoing GDP compliance, this is a good time to review packaging and product information controls.
Start with these checks:
- Review who receives MHRA alerts and defect notifications.
- Check how affected batches are identified.
- Review how packaging and product information issues are logged.
- Check whether accessibility-related issues are included in the process.
- Review whether the Responsible Person has visibility of relevant notices.
- Check whether customers are informed where required.
- Review whether staff know how to handle packaging or labelling queries.
- Check whether supplier communications are stored and traceable.
- Review whether SOPs explain what happens when product information is wrong.
- Check whether actions are recorded and closed properly.
These checks are not about adding unnecessary paperwork.
They are about making sure the business can identify, control and evidence important information.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support.
This may include:
- GDP quality system review
- Responsible Person / GDP quality support
- Product information control review
- Packaging and labelling process review
- SOP and documentation control review
- Supplier and customer communication review
- Defect notification process review
- WDA(H) application readiness
- Compliance route reviews
- Ongoing compliance support
- Inspection readiness support
Our role is to help businesses understand whether their systems are clear, practical and strong enough before small gaps become bigger risks.
We help clients move forward with clarity, control and confidence.
Final Thought
A Braille packaging error may look like a small packaging issue.
But for regulated medicines businesses, it is also a systems issue.
It tests whether the business can receive important information, identify affected stock, communicate clearly, involve the right people and keep records that show what happened.
The strongest businesses are not only focused on the product.
They also control the information around the product.
Need clarity on your packaging controls, product information processes or Responsible Person oversight?
Book a confidential consultation with Stag Global to review your GDP quality system before small gaps become bigger compliance risks.
